High‐mobility Group Protein 1/ Receptor for Advanced Glycation End Products/ Nuclear Factor‐κB Signalling Pathway Contributes to the Pathogenic Process of Striatal Neuron Impairment in the Rat Model of Parkinson's Disease
Brain and Behavior · 2026
DOI: 10.1002/brb3.71133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2026. Verfasst von Yaofeng Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicine, College of Medicine, Jishou University, Jishou, Hunan, China. Hauptthemen laut MEDLINE: Receptor for Advanced Glycation End Products, NF-kappa B, HMGB1 Protein, Corpus Striatum. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hunan Provincial Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.
Themen: Mobilisation
Abstract (Originalsprache)
Background
High‐mobility group protein 1 (HMGB1) is a ligand known to bind to the receptor for advanced glycation end products (RAGE), and it can activate nuclear factor‐κB (NF‐κB) to mediate cellular damage. RAGE and Parkinson's disease (PD) are closely associated, but it remains unclear whether the HMGB1/RAGE/NF‐κB signaling pathway contributes to the pathophysiology of PD.
Methods
PD was induced by administration of 6‐hydroxydopamine (6‐OHDA), while RAGE was inhibited using an inhibitor, FPS‐ZM1. The grip strength test and Morris water maze were used to evaluate sensorimotor and memory skills. Then detect the expression levels of RAGE, HMGB1, and NF‐κB in the striatal sample using immunohistochemistry, western blotting, and RT‐qPCR.
Results
(1) In PD rats, treatment with FPS‐ZM1 improved learning and memory ability and alleviated sensorimotor deficits. (2) The striatum of PD rats exhibited a significant increase in the number of HMGB1‐, RAGE‐, and NF‐κB‐positive cells, which could be reduced through the administration of FPS‐ZM1. Immunofluorescence double‐labeling results indicated that NeuN‐positive neurons were the primary sites of HMGB1‐, RAGE‐, and NF‐κB‐positive responses. Furthermore, these double‐labeled neurons demonstrated a significant increase following 6‐OHDA‐induced depletion of striatal dopamine (DA). However, the FPS‐ZM1 administration considerably attenuated these changes. (3) The treatment of FPS‐ZM1 significantly reduced the increase in protein expression of HMGB1, RAGE, and NF‐κB that followed striatal DA depletion. Similarly, NF‐κB and RAGE mRNA expression were increased by striatal DA deprivation; however, injection of FPS‐ZM1 significantly reduced these changes.
Conclusion
The HMGB1/RAGE/NF‐κB signaling pathway plays a critical role in the pathogenesis of striatal neuronal damage in PD, highlighting its potential as a therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medicine, College of Medicine, Jishou University, Jishou, Hunan, China.
- Neuroscience Laboratory for Cognitive and Developmental Disorders, Department of Anatomy, School of Medicine, Jinan University, Guangzhou, Guangdong, China.
- Department of Pathology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
- Department of Anatomy, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.
Förderung
- National Natural Science Foundation of China
- Hunan Provincial Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Zhu, Y., Du, Z., Sun, L., Huang, Z., Jia, L., Chen, T., Zheng, X., & Lei, W. (2026). High‐mobility Group Protein 1/ Receptor for Advanced Glycation End Products/ Nuclear Factor‐κB Signalling Pathway Contributes to the Pathogenic Process of Striatal Neuron Impairment in the Rat Model of Parkinson's Disease. Brain and Behavior. https://doi.org/10.1002/brb3.71133
Vancouver
Zhu Y, Du Z, Sun L, Huang Z, Jia L, Chen T, et al. High‐mobility Group Protein 1/ Receptor for Advanced Glycation End Products/ Nuclear Factor‐κB Signalling Pathway Contributes to the Pathogenic Process of Striatal Neuron Impairment in the Rat Model of Parkinson's Disease. Brain and Behavior. 2026. doi:10.1002/brb3.71133
BibTeX
@article{Zhu2026,
author = {Zhu, Yaofeng and Du, Zean and Sun, Liping and Huang, Ziyun and Jia, Linju and Chen, Tao and Zheng, Xuefeng and Lei, Wanlong},
title = {High‐mobility Group Protein 1/ Receptor for Advanced Glycation End Products/ Nuclear Factor‐κB Signalling Pathway Contributes to the Pathogenic Process of Striatal Neuron Impairment in the Rat Model of Parkinson's Disease},
journal = {Brain and Behavior},
year = {2026},
doi = {10.1002/brb3.71133}
}
EUVIMED